SCHEMBL31136643

SCHEMBL31136643

Fc1cc(OC(F)F)ccc1CNC12CC(C1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ EPHX2 P34913 2/20 0.39
▸ CTSD P07339 1/20 0.38
▸ BACE1 P56817 1/20 0.38
▸ BACE2 Q9Y5Z0 1/20 0.38
▸ GPR6 P46095 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM1A O60341 1/20 0.35
▸ MAOA P21397 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ TRPV6 Q9H1D0 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ ABL1 P00519 1/20 0.33
▸ DPP8 Q6V1X1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25275967 0.76 GPR6 (0.44) EPHX2BACE1GPR6KDM1AMAOA
SCHEMBL31137114 0.76 KDM1A (0.47) CTSDBACE1BACE2KDM1AHDAC6
SCHEMBL31136681 0.76 CXCR3 (0.47) CTSDBACE1BACE2SCN9AP2RX7
SCHEMBL30471885 0.74 PABPC1 (0.42) KMT2ABACE1GPR6KDM1AMAOA
SCHEMBL23545641 0.74 PABPC1 (0.42) KMT2ABACE1GPR6KDM1AMAOA
SCHEMBL31136678 0.73 IDO1 (0.44) KMT2AEPHX2CTSDBACE1BACE2
SCHEMBL15008655 0.73 TRPV6 (0.47) KMT2ACTSDBACE1BACE2ALDH1A1
SCHEMBL13615572 0.71 ALOX15 (0.37) KMT2AATMEPHX2GPR6ALDH1A1
SCHEMBL15029164 0.70 SCN9A (0.46) KMT2AEPHX2CTSDBACE1BACE2
SCHEMBL1287536 0.70 GPR6 (0.36) KMT2AATMEPHX2GPR6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 — — US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 — — US disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 — — US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 KMT2A 67/4885ATM 461/4885EPHX2 3141/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 KMT2A 52/4885ATM 266/4885EPHX2 2763/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 KMT2A 52/4885ATM 266/4885EPHX2 2763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback